1593-24-4

Basic information

• Product Name: 3-QUINOXALIN-2-YL-ACRYLIC ACID
• Synonyms: 2-Propenoic acid,3-(2-quinoxalinyl)-
• CAS NO: 1593-24-4
• Molecular Formula: C11H8N2O2
• Molecular Weight: 200.19
• Mol File: 1593-24-4.mol
• Article Data: 1

Chemical Properties

• Melting Point: 219-220 °C (decomp)
• Boiling Point: 386.7°Cat760mmHg
• Flash Point: 187.7°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 1.14E-06mmHg at 25°C
• Refractive Index: 1.723
• PKA: 3.04±0.10(Predicted)
• CAS DataBase Reference: 3-QUINOXALIN-2-YL-ACRYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-QUINOXALIN-2-YL-ACRYLIC ACID(1593-24-4)
• EPA Substance Registry System: 3-QUINOXALIN-2-YL-ACRYLIC ACID(1593-24-4)

Safety Data

• Hazardous Substances Data: 1593-24-4(Hazardous Substances Data)

Usage

General Description

3-Quinoxalin-2-yl-acrylic acid is a chemical compound with the molecular formula C13H8N2O2. It is a derivative of quinoxaline, a heterocyclic compound containing a benzene ring fused to a pyrazine ring. 3-QUINOXALIN-2-YL-ACRYLIC ACID has potential applications in pharmaceuticals and material sciences due to its interesting chemical structure and properties. It is also of interest in the field of organic synthesis, where it can be used as a building block for the synthesis of other complex compounds. However, it is important to handle and use this compound with proper safety precautions, as it may have potential hazards if mishandled.

InChI:InChI=1/C11H8N2O2/c14-11(15)6-5-8-7-12-9-3-1-2-4-10(9)13-8/h1-7H,(H,14,15)/b6-5+

Upstream product

• 1593-08-4 Quinoxaline-2-carboxaldehyde 
• 141-82-2 malonic acid 
• 1500-98-7 2-(2-hydroxy-3,3,3-trichlorpropyl)-chinoxalin 
• 7251-61-8 2-methylquinoxaline 

Downstream Products

• 1500-99-8 β-(2-Chinoxalinyl)-propionsaeure 

Relevant articles and documents

CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS

This invention pertains to certain carbamic acid compounds of the following formula, which inhibit HDAC (histone deacetylase) activity wherein: A is independently an unsubstituted or substituted bicyclic C9-10heteroaryl group (e.g., quinolinyl; quinoxalinyl; benzoxazolyl; benzothiazolyl); Q is an acid leader group, and is independently an unsubstituted or substituted, saturated or unsaturated C1 7alkylene group having a backbone length of 4 or less; with the proviso that if A is unsubstituted benzothiazol-2-yl, then Q is an unsaturated group; and with the proviso that if A is unsubstituted quinolin-6-yl, then Q is unsubstituted at the α-position; and with the proviso that A is not benzimidazol-2-yl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both invitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.